Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 target price on shares of Trevena in a research note on Thursday, November 14th.

Trevena Trading Up 2.2 %

Shares of TRVN opened at $1.85 on Monday. Trevena has a 12-month low of $1.13 and a 12-month high of $19.23. The firm has a market capitalization of $1.60 million, a P/E ratio of -0.04 and a beta of 1.05. The firm has a 50-day moving average price of $1.71 and a 200 day moving average price of $3.43.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The firm had revenue of $0.28 million for the quarter. Equities research analysts predict that Trevena will post -23.04 earnings per share for the current fiscal year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.